0001209191-19-015316.txt : 20190304
0001209191-19-015316.hdr.sgml : 20190304
20190304102923
ACCESSION NUMBER: 0001209191-19-015316
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190227
FILED AS OF DATE: 20190304
DATE AS OF CHANGE: 20190304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RENNES FONDATION
CENTRAL INDEX KEY: 0001094515
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37347
FILM NUMBER: 19652274
BUSINESS ADDRESS:
STREET 1: RATIKONSTRASSE 13
STREET 2: VADUZ
CITY: PRINCIPALITY OF LIECHTENSTEIN
STATE: N2
ZIP: FL-9490
BUSINESS PHONE: 41 44 208 25 25
MAIL ADDRESS:
STREET 1: RATIKONSTRASSE 13
STREET 2: VADUZ
CITY: PRINCIPALITY OF LIECHTENSTEIN
STATE: N2
ZIP: FL-9490
FORMER NAME:
FORMER CONFORMED NAME: RENNES FOUNDATION
DATE OF NAME CHANGE: 19990907
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XBiotech Inc.
CENTRAL INDEX KEY: 0001626878
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A1
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8201 E. RIVERSIDE DRIVE
STREET 2: BUILDING 4, SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78744
BUSINESS PHONE: 512-386-2930
MAIL ADDRESS:
STREET 1: 8201 E. RIVERSIDE DRIVE
STREET 2: BUILDING 4, SUITE 100
CITY: AUSTIN
STATE: TX
ZIP: 78744
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-02-27
0
0001626878
XBiotech Inc.
XBIT
0001094515
RENNES FONDATION
R?TIKONSTRASSE 13
VADUZ
N2
FL-9490
LIECHTENSTEIN
0
0
1
0
Common Stock
2019-02-27
4
P
0
5273
8.13
A
3853555
D
Common Stock
2019-02-28
4
P
0
5302
8.19
A
3858857
D
Common Stock
2019-03-01
4
P
0
34999
8.13
A
3893856
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.91 to $8.23, inclusive. The reporting person undertakes to provide to XBiotech Inc., any security holder of XBiotech Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.99 to $8.31, inclusive. The reporting person undertakes to provide to XBiotech Inc., any security holder of XBiotech Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.94 to $8.25, inclusive. The reporting person undertakes to provide to XBiotech Inc., any security holder of XBiotech Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Number is revised to include 150,000 shares which were inadvertently omitted from prior filings.
/s/ Rolf Herter, Director
2019-03-04